novo nordisk's semaglutide failed to slow alzheimer's disease progression Details of studies cast pall on GLP-1 as treatment AD/PD 2026: Novo Nordisk's semaglutide
Description
Resetting the energy homeostasis of the brain cell
The rationale is that even sub-therapeutic doses activate the GLP-1 and GIP receptors enough to produce noticeable appetite modulation without the gastrointestinal side effects that trouble many users during standard initiation
With insulin syringes using fixed (non-detachable) needles, this dead space is minimal, around 0.003 mL or less
Most existing lawsuits against the manufacturers of Ozempic, Wegovy, Mounjaro, and similar drugs involve allegations of gastroparesis, ileus, intestinal obstruction, and other gastrointestinal issues
